Skip to content
OpenCapital
Get started

Royalty Pharma RPRX Q1 2026 earnings

Reported May 6, 2026 · Before market open

Revenue$925.0MBeat by $43.3MDiluted EPS$1.30Beat by $0.08
Revenue estimate$881.7M
EPS estimate$1.22

Next report

Aug 5, 2026 (In 3 weeks)
Revenue estimate$789.5M
EPS estimate$1.27

Financials

Q1 2026

Income statement

See full
Revenue$630.6M+11.0%
Operating income$563.0M+5.4%
Net income$294.7M+23.1%
EPS (diluted)$0.67+21.8%

Balance sheet

See full
Cash & equivalents$586.4M-46.1%
Total debt$9.0B+17.8%
Total equity$9.9B+1.6%
Total assets$19.8B+12.5%

Cash flow

See full
Operating cash flow$718.2M+20.5%

Valuation & ratios

Valuation

as of 07/09/26
See full
Market cap$25.87B+52.4%
Enterprise value$34.26B+44.6%
P/E31.3×+15.7×
P/S10.6×+3.1×

Profitability

See full
Operating margin65.1%-18.9pp
Net margin33.9%-14.4pp

Returns & leverage

See full
Return on equity8.4%-2.7pp
Debt / equity0.9×+0.1×
Current ratio2.7×+1.1×

Versus estimates

Revenue

Q1 2026$925.0MBeat by $43.3M
Q4 2025$874.0MBeat by $67.0MQ3 2025$609.3MMiss by $108.1MQ2 2025$578.7MMiss by $94.3MQ1 2025$568.2MMiss by $137.1MQ4 2024$594.0MMiss by $93.1M

Diluted EPS

Q1 2026$1.30Beat by $0.08
Q4 2025$1.46Beat by $0.17Q3 2025$1.17Beat by $0.18Q2 2025$1.14Beat by $0.11Q1 2025$1.06Beat by $0.11Q4 2024$1.15Beat by $0.16

Ask the moment Royalty Pharma reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Royalty Pharma report Q1 2026 earnings?
Royalty Pharma (RPRX) reported Q1 2026 earnings on May 6, 2026 before market open.
What were Royalty Pharma's Q1 2026 revenue and EPS?
Royalty Pharma reported revenue of $925.0M and diluted EPS of $1.30 for Q1 2026.
Did Royalty Pharma beat estimates in Q1 2026?
Revenue beat the consensus estimate of $881.7M by $43.3M. EPS beat the consensus estimate of $1.22 by $0.08.
How did Royalty Pharma's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 62.8% from $568.2M a year earlier and diluted EPS grew 22.6% from $1.06.
Where can I find Royalty Pharma's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001802768-26-000008) and the 10-Q periodic report (0001802768-26-000009) directly on SEC EDGAR. The filing index links above go to sec.gov.